Erratum: Andrographolide suppress tumor growth by inhibiting TLR4/NF-κB signaling activation in insulinoma (Int J Biol Sci, (2014), 10, 4, (404-414), 10.7150/ijbs.7723);Andrographolide suppress tumor growth by inhibiting TLR4/NF-kB signaling activation in insulinoma

International Journal of Biological Sciences

Volumn 10, Issue 4, 2014, Pages 404-414

  Zhang, Qian Qian ^a   Ding, Yi ^a   Lei, Yan ^a   Qi, Cui Ling ^a   He, Xiao Dong ^a   Lan, Tian ^a   Li, Jiang Chao ^a   Gong, Ping ^a   Yang, Xuesong ^c   Geng, Jian Guo ^b   Wang, Li Jing ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^c MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Andrographolide; Growth; Insulinoma

Indexed keywords

ANDROGRAPHOLIDE; ANTINEOPLASTIC AGENT; DITERPENE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4;

ANIMAL; APOPTOSIS; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; INSULINOMA; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DITERPENES; HUMANS; INSULINOMA; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84897054558     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.49433     Document Type: Erratum

References (29)

1. Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007; 14: 3492-500.
2. Schaefer R. Rare Cancers Europe: joining forces to tackle a common problem. Rare Tumors. 2012; 4: e24.
3. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999; 284: 808-12.
4. Hager JH, Hanahan D. Tumor cells utilize multiple pathways to down-modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis. Ann N Y Acad Sci. 1999; 887: 150-63.
5. Xia YF, Ye BQ, Li YD, Wang JG, He XJ, Lin X, et al. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol. 2004; 173: 4207-17.
6. Iruretagoyena MI, Tobar JA, Gonzalez PA, Sepulveda SE, Figueroa CA, Burgos RA, et al. Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J Pharmacol Exp Ther. 2005; 312: 366-72.
7. Shen YC, Chen CF, Chiou WF. Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect. Br J Pharmacol. 2002; 135: 399-406.
8. Zhou J, Zhang S, Ong CN, Shen HM. Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cells. Biochem Pharmacol. 2006; 72: 132-44.
9. Rajagopal S, Kumar RA, Deevi DS, Satyanarayana C, Rajagopalan R. Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J Exp Ther Oncol. 2003; 3: 147-58.
10. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11: 373-84.
11. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008; 18: 19-26.
12. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007; 133: 1869-81.
13. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007; 317: 124-7.
14. Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, Nagai S, et al. Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway. J Surg Oncol. 2009; 100: 725-31.
15. Chang I, Kim S, Kim JY, Cho N, Kim YH, Kim HS, et al. Nuclear factor kappaB protects pancreatic beta-cells from tumor necrosis factor-alpha-mediated apoptosis. Diabetes. 2003; 52: 1169-75.
16. Handa SS, Sharma A. Hepatoprotective activity of andrographolide from Andrographis paniculata against carbontetrachloride. The Indian journal of medical research. 1990; 92: 276-83.
17. Maciorowski Z, Delic J, Padoy E, Klijanienko J, Dubray B, Cosset JM, et al. Comparative analysis of apoptosis measured by Hoechst and flow cytometry in non-Hodgkin's lymphomas. Cytometry. 1998; 32: 44-50.
18. Wang LJ, Zhao Y, Han B, Ma YG, Zhang J, Yang DM, et al. Targeting Slit-Roundabout signaling inhibits tumor angiogenesis in chemical-induced squamous cell carcinogenesis. Cancer Sci. 2008; 99: 510-7.
19. Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, Zhou H, et al. Liver-Enriched Transcription Factors Regulate MicroRNA-122 That Targets CUTL1 During Liver Development. Hepatology. 2010; 52: 1431-42.
20. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011; 25: 907-16.
21. Singh M, Johnson L. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res. 2006; 12: 5312-28.
22. Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol. 2011; 6: 95-119.
23. Politi K, Pao W. How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol. 2011; 29: 2273-81.
24. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 1985; 315: 115-22.
25. Kumar RA, Sridevi K, Kumar NV, Nanduri S, Rajagopal S. Anticancer and immunostimulatory compounds from Andrographis paniculata. J Ethnopharmacol. 2004; 92: 291-5.
26. Kim TG, Hwi KK, Hung CS. Morphological and biochemical changes of andrographolide-induced cell death in human prostatic adenocarcinoma PC-3 cells. In Vivo. 2005; 19: 551-7.
27. Wang LJ, Zhou X, Wang W, Tang F, Qi CL, Yang X, et al. Andrographolide inhibits oral squamous cell carcinogenesis through NF-kappaB inactivation. J Dent Res. 2011; 90: 1246-52.
28. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006; 66: 3859-68.
29. Wang AC, Su QB, Wu FX, Zhang XL, Liu PS. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells. Eur J Clin Invest. 2009; 39: 157-64.